AXYS Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote ()	3/24/2000 9:26:00 PM
From: bob zagorin	of 455

Medical Technology Stock Letter ? Issue No. 391 4 AXPH will provide Atugen with gene targets that may possibly be useful in treating cancer, and Atugen will apply their technology to identify the function of these gene targets and their possible usefulness as targets for cancer therapeutics. No financial terms of this collaboration were disclosed. AXPH?s stock received a little boost yesterday, despite giving back some of the gain, by an upgrade by an analyst at Robertson Stephens from ?buy? to ?strong buy.? The upgrade was in response to the excessive sell-off in AXPH?s stock, which, in turn, was due to the overreaction to the much-publicized ?issues? surrounding genomics. We view this as a golden opportunity to purchase. AXPH is a buy under $15. *reposted from yahood board.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next